Role of manidipine in the management of patients with hypertension

References

• Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 58, 579–587 (1999).
   PubMedGoogle Scholar
• Staessen JA, Wang JG, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am. J. Hypertens. 15, S85—S93 (2002).
   Google Scholar
• Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. 15, S94—S97 (2002).
   Google Scholar
• ••New classification of calcium antagonist ispresented and discussed.
   Google Scholar
• Angelico P, Guarnieri N, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm. Pharmacol. 51, 709–714 (1999).
   PubMed Web of Science ®Google Scholar
• Van Zvieten PA. The pharmacological prospectives of lipophilic calcium antagonists. Blood Press. 2 (Suppl.), 5–9 (1998).
   PubMedGoogle Scholar
• Lund-Johansen P, Stranden E, Helberg S et al.Quantification of leg edema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. Hypertens. 21, 1003–1010 (2003).
   Google Scholar
• Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 15, 932–940 (2002).
   PubMed Web of Science ®Google Scholar
• Okabe K, Terada K, Kitamura K et al. Selective and long-lasting inhibitory actions of the dihydropyridine derivative, CV4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery. J. Pharmacol. Exp. Ther. 243, 703–710 (1987).
   PubMedGoogle Scholar
• Martindale: The Complete Drug Reference, 32nd Edition. Parfitte K (Ed.). Pharmaceutical Press, MA, USA (1999).
   Google Scholar
• Cataldi M, Taglialatela M, Palagiano F et al.Effects of manidipine and nitrendipine enantiomers on the plateau phase of Ktinduced intracellular Ca2+ increase in GH3 cells. Eur. j Pharmacol. 376, 169–178 (1999).
   PubMed Web of Science ®Google Scholar
• •New findings on the pharmacokinetics of manidipine.
   Google Scholar
• Van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J. Hypertens. 11, S3—S8 (1993).
   Google Scholar
• Fogari R, Zoppi A, Lusardi P, Muggellini A. Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-to-moderate hypertension. Blood Press. 5, S24—S28 (1996).
   Google Scholar
• Nagaoka A. Pharmacologic characteristics of a new calcium antagonist, manidipine: benefical effects on renal circulation and vascular changes. Am. Heart J. 125, 560–565 (1993).
   PubMedGoogle Scholar
• Nakaya H, Hattori Y, Nakao Y, Kenna M. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists. Eur. I Pharmacol. 146, 35–43 (1998).
   Google Scholar
• Shibouta Y, Kitayoshi T, Kitoh G, Nishikawa K. Calcium channel-blocking action of franidipine hydrochloride (CV-4093.2HC1) in vitro and in vivo. Jpn Pharmacol. 48, 463–472 (1988).
   PubMedGoogle Scholar
• Nagaoka A, Kito G, Nagai Y. Antihypertensive action, calcium channel-blocking action and receptor binding activity of manidipine hydrochloride in experimental animals (in Japanese). Jpn Pharmacol. Ther 18, 11–20 (1990).
   Google Scholar
• Pfaffendorf M, Mathy MJ, van Zwieten PA. Effects of manidipine and other calcium antagonists on rat renal arcuate arteries. Am. Heart J. 125, 571–577 (1993).
   PubMedGoogle Scholar
• Roth M, Keul R, Perruchoud AP, Block LH. Manidipine affects rPDF-BB-induced gene transcription of low-density lipoprotein receptors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in human mesangial cells. Am. Heart J. 125, 598–603 (1993).
   PubMedGoogle Scholar
• Radler S, Roth M, Nauck M, Tamm M, Block LH. Ca2tchannel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J MoL Cell. CardioL 27, 2295–2302 (1995).
   PubMedGoogle Scholar
• Fukuzawa M, Satoh J, Ohta S et al. Modulation of tumor necrosis factor-a production with a hypertensive drugs. Immunopharmacology 48, 65–74 (2000).
   PubMed Web of Science ®Google Scholar
• Kakihana M, Suno M, Nagaoka A. Antihypertensive effect of CV-4093.2HCL, a new calcium antagonist, in three rat models of hypertension. Jpn PharmacoL 48, 223–228 (1988).
   PubMedGoogle Scholar
• Tanabe M, Kawazoe K, Kito G et al. Effects of manidipine hydrochloride (CV-4093.2HC1) on systemic hemodynamics, cardiac function and plasma renin activity in conscious renal hypertensive dogs. Jpn PharmacoL Ther. 17, 779–788 (1989).
   Google Scholar
• Tanabe M, Kawazoe K, Kito G et al. Effects of manidipine hydrochloride (CV-4093 12HCID on hemodynamics and cardiac function in conscious normotensive dogs. Jpn PharrnacoL Ther. 17, 55–66 (1989).
   Google Scholar
• Kajino M, Wada Y, Nagai Y, Nagaoka A, Meguro K. Synthesis and biological activities of optical isomers of
   Google Scholar
• - (4-diphenylmethy1-1-piperazinyflethyl methyl 1, 4-dihydro-2, 6-dimethy1-4 (3-nitropheny1)-3,5-pyridibedicarboxylate (manidipine) dihydrochloride. Chem. Pharm. Bull. 37, 2225–2228 (1989).
   PubMedGoogle Scholar
• Takahashi K, Katoh T, Fukunaga M et al. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endothelin. Am. Heart J. 125, 609–619 (1993).
   PubMedGoogle Scholar
• Takabatake T, Ushiogi Y, Ise T et al. Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats. Am. Heart J. 125, 578–581 (1993).
   PubMedGoogle Scholar
• Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles — with special references to glomerular hypertension. Am. J Nephrol 23, 229–244 (2003).
   PubMed Web of Science ®Google Scholar
• •• Complete overview on renal effects of calcium antagonists, particularly focusing on efferent arterioles.
   Google Scholar
• Hansen PB, Jensen BL, Andreasen D, Skott 0. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ. Res. 89, 630–638 (2001).
   PubMed Web of Science ®Google Scholar
• Arima S, Ito S, Omata K et al.Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int. 55, S132—S134 (1996).
   Google Scholar
• Nagaoka A, Shibota M, Hamajo K. Effects of a new dihydropyridine derivate, CV-4093.2HCL, on renal hemodynamics in spontaneously hypertensive rats. Jpn PharmacoL 51, 25–35 (1989).
   PubMedGoogle Scholar
• Kobayashi S, Hishida A. Manidipine attenuates a progressive renal injury in remnant kidneys of rats. Blood Prem. 3, 80–84 (1992).
   Google Scholar
• Kobayashi S, Hishida A. Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. J Lab. Clin. Med. 125, 572–580 (1995).
   PubMedGoogle Scholar
• Fujimaki M, Nagase M, Uchida S. Long-term effect of manidipine on renal function and structure in uninephrectomized spontaneously hypertensive rats. Clin. Exp. PharmacoL PhysioL 24, 506–512 (1997).
   PubMed Web of Science ®Google Scholar
• Reams GP, Villarreal D, Wu Z et al.An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am. Heart J 125, 620–625 (1993).
   PubMedGoogle Scholar
• Sabbatini M, Vitaioli L, Baldoni E et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J. PharmacoL Exp. Ther. 294, 948–954 (2000).
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 35, 775–779 (2000).
   PubMed Web of Science ®Google Scholar
• Sabbatini M, Leonardi A, Testa R et al. Effetcs of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. Cardiovasc. Pharmacol. 39, 39–48 (2002).
   PubMed Web of Science ®Google Scholar
• •• Important article discussing new findings in pharmacodynamics.
   Google Scholar
• Nagaoka A, Shibota M. Natriuretic action of manidipine hydrochloride, a new calcium channel blacker, in spontaneously hypertensive rats. Jpnj PharmacoL 51, 299–301 (1989).
   PubMedGoogle Scholar
• He H, Tamaki T, Aki Y et al. Effects of the calcium antagonist manidipine on renal hemodynamics and function in dogs: comparison with nifedipine. Blood Press. 3, 68–74 (1992).
   Google Scholar
• Nayler WG, Panagiotopoulos S. The antiatheroscleratic effect of the calcium antagonists and their implications in hypertension. Am. Heart J. 125, 626–629 (1993).
   PubMedGoogle Scholar
• Cale LA, Zaghefto F, Pagnin E et al. Effect of manidipine on gene expression and protein level of oxidative stress-related proteins: p22Ph' and HO-1: relevance for antihypertensive and antiremodelling effects. Cardiovasc. PharmacoL 43(4), 531–538 (2004).
   PubMedGoogle Scholar
• •New article on the possible antioxidative effect of manidipine.
   Google Scholar
• Nagaoka A. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. Hypertens. 4, S523—S525 (1986).
   Google Scholar
• Sabbatini M, Tomassoni D, Amenta E Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivates in spontaneously hypertensive rats. Mech. Ageing Dew 122, 2085–2105 (2001).
   PubMed Web of Science ®Google Scholar
• •Article highlighting a new finding on brain protection by manidipine.
   Google Scholar
• Sabbatini M, Tommassoni D, Amenta E Influence of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech. Ageing Dew 122, 795–809 (2001).
   PubMedGoogle Scholar
• Sabbatini M, Tomassoni D, Di Tullio MA, Amenta E Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin. Exp. Hypertens. 24, 727–740 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshhiyama M, Takeuchi K, Kim S et al. Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. Jpn Circ. J. 62, 47–52 (1998).
   PubMedGoogle Scholar
• Tomassoni D, Sabbatini M, Amenta E Effect of different dihydropyridine-type Ca2+ antagonists on ventricle hypertophy and coronary changes in spontaneously hypertensive rats. J Cardiovasc. PharmacoL 41, 544–552 (2003).
   PubMedGoogle Scholar
• Masanori S, Toshihiko S, Koji H et al.Orally administrated benidipine and manidipine prevent ischemia—reperfusion injury in the rat heart. Circj 68, 241–246 (2004).
   PubMed Web of Science ®Google Scholar
• ••Opens new prospectives for manidipine onheart protection.
   Google Scholar
• Kasai Y, Sheu HL, Yabe T, Saso S, Abe K. Acute effect of manidipine on renal blood flow measured by pulse-Doppler flowmeter in normal subjects. Blood Press. 3, S102—S105 (1992).
   Google Scholar
• Celentano A, Crivaro M, Perticone F et al. Antihypertensive effect of manidipine: 24-h monitoring evaluation and Doppler-echocardiographic remarks. Blood Press. 5, S29—S35 (1996).
   Google Scholar
• Fogari R, Zoppi A, Lusardi P et al. Evaluation by 24-h ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10,20 or 40 mg once daily as compared to placebo in treating mild-to-moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study. Blood Press. 5, S16—S23 (1996).
   Google Scholar
• •24-h efficacy of manidipine.
   Google Scholar
• Mancia G, Omboni S, Agabiti-Rosei E et al Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J. Cardiovasc. Pharmacol 35,926–931 (2000).
   PubMed Web of Science ®Google Scholar
• •Efficacy of manidipine in diabetic patients.
   Google Scholar
• Fogari R, Zoppi A, Mugellini A et al.Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives. Cardiovasc. Drugs Ther 13,243–248 (1999).
   PubMed Web of Science ®Google Scholar
• •• Interesting article on efficacy and tolerability in very old hypertensive patients.
   Google Scholar
• Fogari R, Zoppi A, Corradi L et al Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. I Hypertens. 18, 1871–1875 (2000).
   Google Scholar
• ••Demonstrates the impact of severalcalcium antagonists on heart rate.
   Google Scholar
• Zanchetti A, Omboni S, La Commare P et al.Efficacy, tolerability and impact on quality of life and long-term treatment with manidipine or amlodipine in patients with essential hypertension. I Cardiovasc. Pharmacol 38,642–650 (2001).
   PubMed Web of Science ®Google Scholar
• Atarashi K, Takagi M, Minami M et al. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with noninsulin-dependent diabetes mellitus. Blood Press. 1, S130—S134 (1992).
   Google Scholar
• Mancia G, Omboni S, Agabiti-Rosei E et al Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J. Cardiovasc. Pharmacol 35,926–931 (2000).
   PubMed Web of Science ®Google Scholar
• Lai Y-H, Guh J-Y, Chen H-C et al.Effects of manidipine hydrochloride on blood pressure in hypertensive patients — a comparison with nifedipine retard. Kaohsiung J. Med. Sci. 9,625–631 (1993).
   Google Scholar
• Takabatake T, Ohta H, Sasaki T et al Renal effects of manidipine hydrochloride: a new calcium antagonist in hypertensive patients. Euij Clin. Pharmacol 45,321–325 (1993).
   PubMed Web of Science ®Google Scholar
• Yamakado M, Shimomura H, Maehata E. Renoprotection of calcium antagonist: effect of manidipine on urinary microalbumin excretion and lipid peroxidation. Am. J. Hypertens. 9,154 (1996).
   Google Scholar
• Shiba T, Inoue M, Tada H et al Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes mellitus associated nephropathy. Diabetes Res. Clin. Pratt. 47,97–104 (2000).
   PubMed Web of Science ®Google Scholar
• •Neutral impact of manidipine on glucose profile in diabetic hypertensive patients.
   Google Scholar
• Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail 25(5), 681–689 (2003).
   PubMed Web of Science ®Google Scholar
• ••Indicates the possible advantageof manidipine in a patient with renal impairment.
   Google Scholar
• Marusaki S, Shimamoto K, Komura H et al Effects of manidipine on renal sodium and calcium handling in patients with mild essential hypertension. Ther. Res. 14(7), 128–133 (1993).
   Google Scholar
• Karges JR, Mark BE, Stikeleather SJ, Worrell TW. Concurrent validity of upper-extremity volume estimates: comparison of calculated volume derived from girth measurements and water displacement volume. Phys. Ther 83,134–145 (2003).
   PubMed Web of Science ®Google Scholar
• Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. Hypertens. 11,114 (1998).
   Google Scholar
• Fogari R, Malamani GD, Zoppi A et al Manidipine has less edemigenous potential than amlodipine. I Hypertens. 18, S154—S155 (2000).
   Google Scholar
• Casiglia E, Mazza A, Tikhonoff V, Pessina AC. Therapeutic profile of manidipine and lercanidipine in hypertensive patients. Am. Hypertens. (2004) (In press).
   Google Scholar
• Rosillon D, Stockis A, Pali G et al.Food effect on the oral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur. I Drug Metab. Pharmacokinet. 23, 197–202 (1998).
   PubMedGoogle Scholar
• Tateno M. Pharmacokinetic study of CV- 4093 (2 HC1) at single dose on healthy subjects. Rinsho Iyaku 5,1765–1777 (1989).
   Google Scholar
• Deroubaix X, Lins RL, Lens S et al.Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int. I Clin. Pharmacol Ther 36, 386–391 (1998).
   PubMed Web of Science ®Google Scholar
• Chiesi Farmaceutici SPA/Takeda Italia Farmaceutici. Summary of product characteristics. Chiesi Farmaceutici SPA/Takeda Italia Farmaceutici (2000).
   Google Scholar
• Katoh M, Nakajima M, Shimada N et al Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug interactions. Eur j Clin. Pharmacol 55(11–12), 843–852 (2000).
   Google Scholar
• Hashimoto Y, Shimizu A, Kuroda T et al. Effect of dihydropyridine calcium channel blockers on the plasma digoxin level. Jpn Clin. Pharmacol Ther 27(4), 665–671 (1996).
   Google Scholar
• Takara K, Sakaeda T, Tanigawara Y et al Effects of 12 Ca2+ anatgonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Euij Pharm. Set. 16(3), 159–165 (2002).
   PubMedGoogle Scholar
• Stockis A, Gengler C, Goethals F et al Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung53 (9), 627–634 (2003).
   Google Scholar
• Ogihara T Practitioner&s trial on the efficacy of Antihypertensive Treatment in the Elderly—Hypertension (the PATE—Hypertension study) in Japan. Am. Hypertens. 13(5), 461–467 (2000).
   Google Scholar
• ••Important trial in elderlyhypertensive patients.
   Google Scholar
• Ogihara T, Nakagawa M, Ishikawa H et al. Effect of manidipine, a novel calcium channel blacker, on quality of life in hypertensive patients. Blood Press 3, S135—S139 (1992).
   Google Scholar
• Hase MI, Hase MO, Igawa S et al. Reduction of left ventricular mass by manidipine hydrochloride. Am. J. Hypertens. 11(4), A81 (1998).
   Google Scholar
• Nagasawa K, Kitamoto K, Nagasawa T A 3- year long-term evaluation of the efficacy and safety of manidipine hydrochloride (Calslot tablet) in the elderly with essential hypertension: a multicenter collaborative study. Rinsho Kenkyu 74(10), 2630–2638 (1997).
   Google Scholar
• Kaneko Y, Fukiyarna K, Iimura 0 et al. Clinical study of manidipine hydrochloride in essential hypertension: a double-blind controlled study with nicardipine hydrochloride. J. Clin. Exp. Med. 151(8), 471–492 (1989).
   Google Scholar
• Tomiyama H, Kimura Y, Saluma Y et al. Effects of an ACE inhibitor and calcium channel blacker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild-to-moderate hypertension. Arn. Hypertens. 11,682–689 (1998).
   PubMed Web of Science ®Google Scholar
• Saku K, Zhang B, Hirata K et al. Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in-patients with mild-to-moderate essential hypertension: a randomized trial with 1-year follow-up. Clin. Ther 14,813–820 (1992).
   PubMedGoogle Scholar
• Karpati 13, Alberici M, Tocci G et al Long- term tolerability and efficacy of the fixed combination of manidipine and delapril in pateints with essential hypertension. High Blood Press. Cardiovasc. Prey 10(2), 81–86 (2003).
   Google Scholar
• ••Review on the new fixed combinationmanidipine and delapril.
   Google Scholar
• Mizuno K, Haga H, Takahashi M et al Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders. Blood Press. 3, S119—S123 (1992).
   Google Scholar
• Saruta T, Suzuki H. Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial. Am. Heart 125(2), 630–634 (1993).
   PubMedGoogle Scholar
• Crivaro M, Celentano A, Palmieri V et al. Mild arterial hypertension and impaired glucose tolerance: short-term effects of manidipine hydrochloride. Ady Ther13 (6), 365–372 (1996).
   Google Scholar
• Oliviero M, Turco S, Tammaro P et al. Manidipina versus amlodipina in Type II diabetic patients with hypertension: comparison in double-blind. Diabetologia 41 (1), A340 (1998) (Abstract).
   Google Scholar
• Fogari R, Mugellini A, Zoppi A et al Effect of manidipine and lisinopril on albuminuria and ventricular mass in diabetic hypertensive patients with microalbuminuria. Am. I Hypertens. 15(4), A22 (2002) (Abstract).
   Google Scholar
• Suzuki S, Ohtomo M, Satoh Y et al.Effect of manidipine and delapril on insulin sensitivity in Type 2 diabetic patients with essential hypertension. Diabetes Res. Clin PracL 33,43–51 (1996).
   PubMed Web of Science ®Google Scholar
• Iimura 0, Shimamoto K, Masuda A et al. Effects of a calcium channel blacker, manidipine, on insulin sensitivity in essential hypertensives. I Diabetes Complicat. 9,215–219 (1995).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. j Am. Med. Assoc. 289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension—European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension—European Society of Cardiology Guidelines for the management of arterial hypertension. I Hypertens. 21, 1011–1053 (2003).
   Google Scholar
• Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). Br. Med .J 328,634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomized double-blind comparison of placebo and active treatment of older patients with isolated systolic hypertension. The Syst—Eur Trial Investigators. Lancet350, 757–764 (1997).
   Google Scholar
• Tuomilehto J, Rasyenyte D, Birkenhager WH et al Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in European Trial Investigators. N Engl. I Med. 340,677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Voyaki SM, Staessen JA, Thijs L et al. Follow- up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in European (Syst—Eur) Trial Investigators. Hypertens. 19,511–519 (2001).
   Google Scholar
• Forette F, Amery A, Staessen JA et al Is prevention of vascular dementia possible? The Syst—Eur Vascular Dementia Project. Aging 3, 373–382 (1991).
   PubMedGoogle Scholar
• Seux ML, Thijs L, Forette F et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst—Eur vascular dementia project. I Hypertens. 16,963–969 (1998).
   Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension (Syst—Eur) Trail. Lancet352, 1347–1351 (1998).
   Google Scholar
• Pitt B, Byington RB Fuberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 102,1503–1510 (2000).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet358, 1305–1315 (2001).
   Google Scholar
• ••Very exhaustive meta-analysis onantihypertensive treatment.
   Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a qualitative overview updated until 1 March 2003. Hypertens. 21, 1055–1076 (2003).
   Web of Science ®Google Scholar
• Pahor M, Guralnik JM, Furberg CD et al. Risk of GI hemorrhage with calcium antagonists in hypertensive people over 67 years old. Lancet347, 1061–1065 (1996).
   Google Scholar
• Jick H, Jick S, Derby LE et al. Calcium channel blockers and risk of cancer. Lancet 349,525–528 (1997).
   PubMed Web of Science ®Google Scholar
• Pstay BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. J Am. Med. Assoc. 277,739–745 (1997).
   Google Scholar
• Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first-line antihypertensive agents. Arn. Hypertens. 9(2), 122–125 (1996).
   PubMedGoogle Scholar
• Salvetti A, Mattel P, Sudano I. Renal protection and antihypertensive drugs: current status. Drugs 57(5), 665–693 (1999).
   PubMedGoogle Scholar
• Hansson L, Zanchetti A, Carruthers SG et al Effects of intensive blood prressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Tratement (HOT) randomized trial. HOT Study Group. Lancet 351,1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. j Med. 345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Fogari R, Malarnani G, Derosa G et al. Effect of delapril addition to manidipine on ankle edema and subcutaneous tissue pressure in hypertensive patients. Am. j Hypertens. 16, A113 (2003) (Abstract).
   Google Scholar
• Mugellini A, Preti P, Zoppi A et al.Effect of delapril—mandipine combination vs. irbesartan—hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. Hum. Hypertens. 18(10), 687–691 (2004).
   PubMedGoogle Scholar